VisionLifesciences

Pharma & Biotech Business Development Advisors

Your partner in cross-border licensing, partnerships, and deal-making for global pharma and life sciences.

In-Licensing

Acquire rights to innovative therapeutics and technologies.

Out-Licensing

Monetize your IP and product portfolios globally.

Strategic Partnerships

Build cross-border alliances in pharma and biotech.

Global Network

Deep connections across Asia, Europe, and USA.

Vision Lifesciences - Pharma and Biotech Business Development Advisors

Your Partner in Cross-Border Life Sciences Deals

We facilitate global partnerships and financing in life sciences, connecting Asia, Europe, and USA to accelerate innovation to market.

Global
Tri-Continental Network
Proven
Cross-Border Deal Expertise
Billions
In Transaction Opportunity

Solutions for Life Sciences Cross-Border Collaborations

In-Licensing. Acquire rights to innovative therapeutics and technologies from global partners.

In-licensing deals and partnerships

Out-Licensing. Monetize your IP and product portfolios through strategic licensing agreements.

Out-licensing opportunities

Strategic Partnerships. Build cross-border alliances for drug development, manufacturing, and commercialization.

Connected
Global Partner Ecosystem

NewCo Formation. Spin off assets into new independent entities to access global capital and expertise.

Launched
Multiple NewCos to Market

Capital Access. Connect clients with investors and structure financial deals from seed to late-stage.

Funded
Capital Raised

Core Capabilities for Pharmaceutical and Biotech Success

Our specialized knowledge and vast connections make us the ideal catalyst for cross-border collaborations in the life sciences industry.

Maximize value in licensing transactions.

We facilitate in-licensing agreements, balancing upfront payments, milestones, and royalties for optimal outcomes. Our expertise ensures you secure the right assets at the right terms.
In-Licensing

Latest Insights

Looking for hidden opportunities in global pharma? Our insights reveal them.

Biotech Licensing Deal Tracker 2026: Top Deals, Trends & Strategic Analysis

Biotech Licensing Deal Tracker 2026: Top Deals, Trends & Strategic Analysis

$250B+ across 516 licensing deals in 2025. Average deal size surges 76% in 2026. Track the biggest transactions and what they mean for your BD strategy.

Gene Therapy Market 2026: Approved Products, Pipeline & Licensing Deals

Gene Therapy Market 2026: Approved Products, Pipeline & Licensing Deals

Zolgensma ($1.24B), Elevidys ($820M+), and CRISPR-based Casgevy are transforming rare disease. Track AAV, CRISPR, and in vivo gene therapy licensing opportunities.

Orphan Drug Designation & Rare Disease Licensing 2026: Market & Strategy Guide

Orphan Drug Designation & Rare Disease Licensing 2026: Market & Strategy Guide

The $217B orphan drug market covers only 5% of rare diseases. 7-year exclusivity, premium pricing, and BioMarin's $4.8B Amicus deal signal massive BD opportunity.

Frequently Asked Questions

Looking for a Collaboration?

Let's discuss how we can help you accelerate your cross-border deals in pharma and life sciences.